8-K: DocGo Reports Strong Q1 2024 Results with Record Adjusted EBITDA

DocGo announced a profitable first quarter of 2024, highlighted by a significant increase in revenue and adjusted EBITDA, despite a revised full-year revenue guidance due to an accelerated wind-down of migrant-related services.

Summary

• DocGo reported a strong first quarter for 2024, with total revenue reaching $192.1 million, a 70% increase compared to $113.0 million in the same period last year.
• The company achieved a net income of $10.6 million, a substantial turnaround from a net loss of $3.9 million in Q1 2023, representing a 372% increase.
• Adjusted EBITDA for the quarter was a record $24.1 million, a 330% increase from $5.6 million in the first quarter of 2023.
• Mobile Health Services revenue saw a 97% increase, reaching $143.9 million, while Transportation Services revenue grew by 20% to $48.2 million.
• Gross margin improved to 35.0% from 28.1% in the same quarter of the previous year.
• Due to an accelerated wind-down of migrant-related services, the company revised its 2024 revenue guidance to $600-$650 million, down from $720-$750 million.
• The company expects its base business revenue (medical transportation and non-migrant mobile health) to be $280-$300 million in 2024 and grow by over 30% in 2025 with an adjusted EBITDA margin exceeding 10%.
• The 2024 adjusted EBITDA guidance was revised to $65-$75 million, down from the previous range of $80-$85 million.
• Cash flow from operations for 2024 is now expected to be $70-$80 million, up from the prior forecast of $65-$75 million.
• The company repurchased approximately 2.7 million shares at an average price of $3.69 per share and has $26 million remaining under the current buyback plan.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong Q1 results, but the revised guidance and accelerated wind-down of migrant services temper the overall sentiment. The company's base business growth and new contracts are encouraging, but the reduced revenue forecast is a concern.

Positives

• The company achieved a substantial increase in revenue, growing by 70% year-over-year.
• DocGo turned a net loss into a net income of $10.6 million, demonstrating improved profitability.
• Adjusted EBITDA reached a record high, showing strong operational performance.
• The company's mobile health services segment experienced significant growth, nearly doubling its revenue.
• Gross margins improved, indicating better cost management and pricing strategies.
• The company increased its cash flow from operations forecast for 2024.
• The share repurchase program demonstrates confidence in the company's value.
• The company has expanded its health plan contracts to include two of the five largest health insurance companies in the United States.
• New patient monitoring contracts were signed with two large cardiology practices.
• The company launched new mobile X-Ray and virtual care programs.

Negatives

• The company revised its 2024 revenue guidance downwards due to the accelerated wind-down of migrant-related services.
• The adjusted EBITDA guidance for 2024 was also revised downwards.
• The company's cash and cash equivalents decreased from $127.5 million to $58.9 million year-over-year.

Risks

• The accelerated wind-down of migrant-related services will negatively impact revenue in the coming quarters.
• The company faces risks related to its ability to maintain and expand its contracts with healthcare providers and clients.
• The company operates in a highly competitive industry, which could impact its ability to maintain market share.
• The company's reliance on government contracts exposes it to potential changes in government policies.
• The company's financial performance is subject to macroeconomic factors, including inflation and potential recession.
• The company is subject to risks related to cybersecurity incidents.
• The company is subject to risks related to legal proceedings and compliance risk.

Future Outlook

The company expects its base business to grow by over 30% in 2025 with an adjusted EBITDA margin exceeding 10%. The company has revised its 2024 revenue guidance to $600-$650 million and adjusted EBITDA guidance to $65-$75 million due to the accelerated wind-down of migrant-related services. Cash flow from operations for 2024 is expected to be $70-$80 million.

Management Comments

• Lee Bienstock, Chief Executive Officer of DocGo, stated that he is extremely pleased with the company's operational execution and that the accelerated wind down of migrant work will allow the company to redirect resources to other growth opportunities.
• Norm Rosenberg, Chief Financial Officer of DocGo, noted that the company's financial performance during the first quarter was exceptionally strong, highlighted by improvements in gross margins and overall profitability.

Industry Context

The announcement reflects a growing trend in the healthcare industry towards mobile and virtual care solutions. DocGo's expansion into health plan contracts and new service offerings aligns with the industry's focus on value-based care and preventative health measures. The company's growth in mobile health services and patient monitoring is consistent with the increasing demand for accessible and convenient healthcare options.

Comparison to Industry Standards

• DocGo's 70% revenue growth in Q1 2024 significantly outpaces the average growth rate for healthcare service providers, which typically ranges from 5-15% annually.
• The 330% increase in adjusted EBITDA is exceptional compared to industry peers, such as American Medical Response (AMR) and Global Medical Response (GMR), which typically see more modest EBITDA growth.
• The improvement in gross margin to 35% is competitive with other healthcare service companies, but the company needs to maintain this level of performance to remain competitive.
• While companies like Teladoc Health and Amwell are leaders in the telehealth space, DocGo's focus on mobile health services and integrated medical transport provides a unique value proposition.
• The company's share repurchase program is a positive sign, but it needs to be balanced with the need for capital to fund future growth and acquisitions.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the revised revenue guidance and the accelerated wind-down of migrant-related services, but the strong Q1 results and share repurchase program are positive.
• Employees may experience changes in workload and responsibilities as the company redirects resources to new growth opportunities.
• Customers will benefit from the company's expanded service offerings and new programs.
• Suppliers may see changes in demand as the company adjusts its operations.
• Creditors will be impacted by the company's financial performance and cash flow.

Next Steps

• The company will focus on expanding its programs with major insurance companies and its medical transportation business with hospital systems.
• The company will redirect resources and management efforts to support various growth opportunities with insurance companies, hospitals, and other population health programs.
• The company will continue to execute its share repurchase program.
• The company will continue to monitor and address the impacts of the cybersecurity incident.

Key Dates

Keywords

mobile health, adjusted EBITDA, revenue, net income, healthcare, telehealth, medical transportation, gross margin, cash flow, share repurchase